Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMPRSS4 | Q9NRS4 | 12/20 | 0.71 |
| ▸ | P2RX1 | P51575 | 10/20 | 0.68 |
| ▸ | P2RX4 | Q99571 | 6/20 | 0.64 |
| ▸ | P2RX7 | Q99572 | 6/20 | 0.64 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.60 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.60 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.60 |
| ▸ | KCNMA1 | Q12791 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | IKBKB | O14920 | 1/20 | 0.56 |
| ▸ | CHUK | O15111 | 1/20 | 0.56 |
| ▸ | KDR | P35968 | 1/20 | 0.56 |
| ▸ | FLT3 | P36888 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | MYLK | Q15746 | 1/20 | 0.56 |
| ▸ | MAP4K5 | Q9Y4K4 | 1/20 | 0.56 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26096765 | 0.89 | P2RX1 (0.76) | TMPRSS4P2RX1P2RX4P2RX7TAS1R3 | |
| SCHEMBL18341118 | 0.85 | P2RX1 (0.74) | TMPRSS4P2RX1P2RX4P2RX7TAS1R3 | |
| SCHEMBL30771736 | 0.85 | P2RX1 (0.74) | TMPRSS4P2RX1P2RX4P2RX7TAS1R3 | |
| SCHEMBL14886085 | 0.83 | TMPRSS4 (1.00) | TMPRSS4P2RX1P2RX4P2RX7MEN1 | |
| SCHEMBL27786761 | 0.83 | P2RX1 (0.76) | TMPRSS4P2RX1P2RX4P2RX7TAS1R3 | |
| SCHEMBL23303861 | 0.82 | P2RX1 (0.70) | TMPRSS4P2RX1P2RX4P2RX7TAS1R3 | |
| SCHEMBL13189546 | 0.82 | P2RX1 (0.70) | TMPRSS4P2RX1P2RX4P2RX7TAS1R3 | |
| SCHEMBL23303643 | 0.82 | TMPRSS4 (0.81) | TMPRSS4P2RX1P2RX4P2RX7MEN1 | |
| SCHEMBL11683279 | 0.81 | P2RX1 (0.82) | TMPRSS4P2RX1P2RX4P2RX7KCNMA1 | |
| SCHEMBL30771744 | 0.81 | P2RX1 (1.00) | TMPRSS4P2RX1P2RX4P2RX7TAS1R3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7671058-B2 | N-(3,4-disubstituted phenyl) salicylamide derivatives | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2010-03-02 | — | — | US | disclosed |
| US-7671058-B2 | N-(3,4-disubstituted phenyl) salicylamide derivatives | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2010-03-02 | — | — | US | disclosed |
| US-7671058-B2 | N-(3,4-disubstituted phenyl) salicylamide derivatives | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2010-03-02 | — | — | US | disclosed |
| US-20080227784-A1 | N-(3,4-disubstituted phenyl) salicylamide derivatives | INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) | 2008-09-18 | — | — | US | disclosed |
| US-20080227784-A1 | N-(3,4-disubstituted phenyl) salicylamide derivatives | INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) | 2008-09-18 | — | — | US | disclosed |
| US-20080227784-A1 | N-(3,4-disubstituted phenyl) salicylamide derivatives | INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) | 2008-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080227784-A1 | N-(3,4-disubstituted phenyl) salicylamide derivatives | STAT6, RELA, NFKB2 | TMPRSS4 3190/4885P2RX1 3116/4885P2RX4 2985/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.